Cushing's syndrome: A structured short- and long-term management plan for patients in remission

European Journal of Endocrinology

Volumn 169, Issue 5, 2013, Pages

  Ragnarsson, Oskar ^a,b   Johannsson, Gudmundur ^a,b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; HYDROCORTISONE;

ACTH SECRETING ADENOMA; ADRENAL CORTEX ADENOMA; ADRENAL INSUFFICIENCY; ADRENALECTOMY; BODY MASS; BONE DENSITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COGNITIVE DEFECT; CUSHING SYNDROME; DIABETES INSIPIDUS; DRUG DOSE REDUCTION; FRAGILITY FRACTURE; GROWTH HORMONE DEFICIENCY; HUMAN; HYPERCORTISOLISM; HYPOPITUITARISM; HYPOTHYROIDISM; LONG TERM CARE; MENTAL DISEASE; MORTALITY; NONFUNCTIONING PITUITARY ADENOMA; NONHUMAN; OSTEOPOROSIS; POSTOPERATIVE CARE; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; REVIEW; SIDE EFFECT; TRANSSPHENOIDAL HYPOPHYSECTOMY;

CASE MANAGEMENT; COGNITION DISORDERS; CUSHING SYNDROME; HUMANS; LONG-TERM CARE; POSTOPERATIVE PERIOD; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84886296711     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-0534     Document Type: Review

References (119)

1. Cushing H. The pituitary body and its disorders, clinical states produced by disorders of the hypophysis cerebri. Philadelphia, London: J.B. Lippincott Company, 1912.
2. Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bulletin of the Johns Hopkins Hospital 1932 50 137-195.
3. Albright F. Cushing's syndrome; its pathology and physiology, its relationship to the adrenogenital syndrome, and its connection with the problem of the reaction of the body to injurious agents. Harvey Lectures 1943 38 123-186.
4. Newell-Price J, Bertagna X, Grossman AB & Nieman LK. Cushing's syndrome. Lancet 2006 367 1605-1617. (doi:10.1016/S0140-6736(06)68699-6)
5. Valassi E, Santos A, Yaneva M, Toth M, Strasburger CJ, Chanson P, Wass JA, Chabre O, Pfeifer M, Feelders RA et al. The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. European Journal of Endocrinology 2011 165 383-392. (doi:10.1530/EJE-11-0272)
6. Lindholm J, Juul S, Jorgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, Hagen C, Jorgensen J, Kosteljanetz M, Kristensen L et al. Incidence and late prognosis of Cushing's syndrome: a population-based study. Journal ofClinicalEndocrinology and Metabolism 2001 86 117-123. (doi:10.1210/jc.86.1. 117)
7. Bolland MJ, Holdaway IM, Berkeley JE, Lim S, Dransfield WJ, Conaglen JV, Croxson MS, Gamble GD, Hunt PJ & Toomath RJ.Mortality and morbidity in Cushing's syndrome in New Zealand. Clinical Endocrinology 2011 75 436-442. (doi:10.1111/j.1365-2265.2011.04124.x)
8. Etxabe J & Vazquez JA. Morbidity and mortality in Cushing's disease: an epidemiological approach. Clinical Endocrinology 1994 40 479-484. (doi:10.1111/j.1365-2265.1994.tb02486.x)
9. Arnardottir S & Sigurjonsdottir HA. The incidence and prevalence of Cushing's disease may be higher than previously thought: results from a retrospective study in Iceland 1995 through 2009. Clinical Endocrinology 2011 74 792-793.
10. Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ et al. Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. Journal of Clinical Endocrinology and Metabolism 2008 93 2454-2462. (doi:10.1210/jc.2007-2734)
11. Rees DA, Hanna FW, Davies JS, Mills RG, Vafidis J & Scanlon MF. Long-term follow-up results of transsphenoidal surgery for Cushing's disease in a single centre using strict criteria for remission. Clinical Endocrinology 2002 56 541-551. (doi:10.1046/j.1365-2265.2002.01511.x)
12. Salenave S, Gatta B, Pecheur S, San-Galli F, Visot A, Lasjaunias P, Roger P, Berge J, Young J, Tabarin A et al. Pituitary magnetic resonance imaging findings do not influence surgical outcome in adrenocorticotropin-secreting microadenomas. Journal of Clinical Endocrinology and Metabolism 2004 89 3371-3376. (doi:10.1210/jc.2003-031908)
13. Trainer PJ, Lawrie HS, Verhelst J, Howlett TA, Lowe DG, Grossman AB, Savage MO, Afshar F & Besser GM. Transsphenoidal resection in Cushing's disease: undetectable serum cortisol as the definition of successful treatment. Clinical Endocrinology 1993 38 73-78. (doi:10.1111/j.1365-2265.1993.tb00975.x)
14. Prevedello DM, Pouratian N, Sherman J, Jane JA Jr, Vance ML, Lopes MB & Laws ER Jr. Management of Cushing's disease: outcome in patients with microadenoma detected on pituitary magnetic resonance imaging. Journal of Neurosurgery 2008 109 751-759. (doi:10.3171/JNS/2008/109/10/0751)
15. Hammer GD, Tyrrell JB, Lamborn KR, Applebury CB, Hannegan ET, Bell S, Rahl R, Lu A &Wilson CB. Transsphenoidal microsurgery for Cushing's disease: initial outcome and longterm results. Journal of Clinical Endocrinology and Metabolism 2004 89 6348-6357. (doi:10.1210/jc.2003-032180)
16. Hughes NR, Lissett CA & Shalet SM. Growth hormone status following treatment for Cushing's syndrome. Clinical Endocrinology 1999 51 61-66. (doi:10.1046/j.1365-2265.1999.00738.x)
17. Pecori Giraldi F, Andrioli M, De Marinis L, Bianchi A, Giampietro A, De Martin M, Sacco E, Scacchi M, Pontecorvi A & Cavagnini F. Significant GH deficiency after long-term cure by surgery in adult patients with Cushing's disease. European Journal of Endocrinology 2007 156 233-239. (doi:10.1530/eje.1.02329)
18. Patil CG, Prevedello DM, Lad SP, Vance ML, Thorner MO, Katznelson L & Laws ER Jr. Late recurrences of Cushing's disease after initial successful transsphenoidal surgery. Journal of Clinical Endocrinology and Metabolism 2008 93 358-362. (doi:10.1210/jc.2007-2013)
19. Atkinson AB, Kennedy A, Wiggam MI, McCance DR & Sheridan B. Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance. Clinical Endocrinology 2005 63 549-559. (doi:10.1111/j.1365-2265.2005.02380.x)
20. Bertagna X & Guignat L. Approach to the Cushing's disease patient with persistent/recurrent hypercortisolism after pituitary surgery. Journal of Clinical Endocrinology and Metabolism 2013 98 1307-1318. (doi:10.1210/jc.2012- 3200)
21. Plotz CM, Knowlton AI & Ragan C. The natural history of Cushing's syndrome. American Journal of Medicine 1952 13 597-614. (doi:10.1016/0002- 9343(52)90027-2)
22. Clayton RN, Raskauskiene D, Reulen RC & Jones PW. Mortality and morbidity in Cushing's disease over 50 years in Stokeon- Trent, UK: audit and meta-analysis of literature. Journal of Clinical Endocrinology and Metabolism 2011 96 632-642. (doi:10.1210/jc.2010-1942)
23. Dekkers OM, Horvath-Puho E, Jorgensen JO, Cannegieter SC, Ehrenstein V, Vandenbroucke JP, Pereira AM & Sorensen HT. Multisystem morbidity and mortality in Cushing's syndrome: a cohort study. Journal of Clinical Endocrinology and Metabolism 2013 98 2277-2284. (doi:10.1210/jc.2012-3582)
24. Dekkers OM, Biermasz NR, Pereira AM, Roelfsema F, van Aken MO, Voormolen JH & Romijn JA. Mortality in patients treated for Cushing's disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. Journal of Clinical Endocrinology and Metabolism 2007 92 976-981. (doi:10.1210/jc.2006-2112)
25. Mancini T, Kola B, Mantero F, Boscaro M & Arnaldi G. High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clinical Endocrinology 2004 61 768-777. (doi:10.1111/j.1365- 2265.2004.02168.x)
26. Giordano R, Picu A, Marinazzo E, D'Angelo V, Berardelli R, Karamouzis I, Forno D, Zinna D, Maccario M, Ghigo E et al. Metabolic and cardiovascular outcomes in patients with Cushing's syndrome of different aetiologies during active disease and 1 year after remission. Clinical Endocrinology 2011 75 354-360. (doi:10.1111/j.1365-2265.2011.04055.x)
27. Toja PM, Branzi G, Ciambellotti F, Radaelli P, De Martin M, Lonati LM, Scacchi M, Parati G, Cavagnini F & Pecori Giraldi F. Clinical relevance of cardiac structure and function abnormalities in patients with Cushing's syndrome before and after cure. Clinical Endocrinology 2012 76 332-338. (doi:10.1111/j.1365-2265.2011.04206.x)
28. Pereira AM, Delgado V, Romijn JA, Smit JW, Bax JJ & Feelders RA. Cardiac dysfunction is reversed upon successful treatment of Cushing's syndrome. European Journal of Endocrinology 2010 162 331-340. (doi:10.1530/EJE-09-0621)
29. Yiu KH, Marsan NA, Delgado V, Biermasz NR, Holman ER, Smit JW, Feelders RA, Bax JJ & Pereira AM. Increased myocardial fibrosis and left ventricular dysfunction in Cushing's syndrome. European Journal of Endocrinology 2012 166 27-34. (doi:10.1530/EJE-11-0601)
30. Faggiano A, Pivonello R, Spiezia S, De Martino MC, Filippella M, Di Somma C, Lombardi G & Colao A. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. Journal of Clinical Endocrinology and Metabolism 2003 88 2527-2533. (doi:10.1210/jc.2002-021558)
31. Colao A, Pivonello R, Spiezia S, Faggiano A, Ferone D, Filippella M, Marzullo P, Cerbone G, Siciliani M & Lombardi G. Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. Journal of Clinical Endocrinology and Metabolism 1999 84 2664-2672. (doi:10.1210/jc.84.8.2664)
32. Barahona MJ, Resmini E, Vilades D, Pons-Llado G, Leta R, Puig T & Webb SM. Coronary artery disease detected by multislice computed tomography in patients after long-term cure of Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 2013 98 1093-1099. (doi:10.1210/jc.2012-3547)
33. Kristo C, Jemtland R, Ueland T, Godang K & Bollerslev J. Restoration of the coupling process and normalization of bone mass following successful treatment of endogenous Cushing's syndrome: a prospective, long-term study. European Journal of Endocrinology 2006 154 109-118. (doi:10.1530/eje.1.02067)
34. Vestergaard P, Lindholm J, Jorgensen JO, Hagen C, Hoeck HC, Laurberg P, Rejnmark L, Brixen K, Kristensen LO, Feldt-Rasmussen U et al. Increased risk of osteoporotic fractures in patients with Cushing's syndrome. European Journal of Endocrinology 2002 146 51-56. (doi:10.1530/eje.0.1460051)
35. Barahona MJ, Sucunza N, Resmini E, Fernandez-Real JM, RicartW, Moreno-Navarrete JM, Puig T,Wagner AM, Rodriguez-Espinosa J, Farrerons J et al. Deleterious effects of glucocorticoid replacement on bone in women after long-term remission of Cushing's syndrome. Journal of Bone and Mineral Research 2009 24 1841-1846. (doi:10.1359/jbmr.090505)
36. Hermus AR, Smals AG, Swinkels LM, Huysmans DA, Pieters GF, Sweep CF, Corstens FH & Kloppenborg PW. Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 1995 80 2859-2865. (doi:10.1210/jc.80.10.2859)
37. Futo L, Toke J, Patocs A, Szappanos A, Varga I, Glaz E, Tulassay Z, Racz K & Toth M. Skeletal differences in bone mineral area and content before and after cure of endogenous Cushing's syndrome. Osteoporosis International 2008 19 941-949. (doi:10.1007/s00198-007-0514-x)
38. Kawamata A, Iihara M, Okamoto T & Obara T. Bone mineral density before and after surgical cure of Cushing's syndrome due to adrenocortical adenoma: prospective study. World Journal of Surgery 2008 32 890-896. (doi:10.1007/s00268-007-9394-7)
39. Lindsay JR, Nansel T, Baid S, Gumowski J & Nieman LK. Longterm impaired quality of life in Cushing's syndrome despite initial improvement after surgical remission. Journal of Clinical Endocrinology and Metabolism 2006 91 447-453. (doi:10.1210/jc.2005-1058)
40. Johnson MD,Woodburn CJ & Vance ML. Quality of life in patients with a pituitary adenoma. Pituitary 2003 6 81-87. (doi:10.1023/B:PITU.0000004798. 27230.ed)
41. Sonino N & Fava GA. Psychosomatic aspects of Cushing's disease. Psychotherapy and Psychosomatics 1998 67 140-146. (doi:10.1159/000012274)
42. Loosen PT, Chambliss B, DeBold CR, Shelton R & Orth DN. Psychiatric phenomenology in Cushing's disease. Pharmacopsychiatry 1992 25 192-198. (doi:10.1055/s-2007-1014405)
43. Fava GA, Morphy MA & Sonino N. Affective prodromes of medical illness. Psychotherapy and Psychosomatics 1994 62 141-145. (doi:10.1159/ 000288916)
44. Whelan TB, Schteingart DE, Starkman MN & Smith A. Neuropsychological deficits in Cushing's syndrome. Journal of Nervous and Mental Disease 1980 168 753-757. (doi:10.1097/00005053-198012000-00008)
45. Starkman MN, Schteingart DE & Schork MA. Correlation of bedside cognitive and neuropsychological tests in patients with Cushing's syndrome. Psychosomatics 1986 27 508-511. (doi:10.1016/S0033-3182(86)72657-1)
46. Starkman MN, Gebarski SS, Berent S & Schteingart DE. Hippocampal formation volume, memory dysfunction, and cortisol levels in patients with Cushing's syndrome. Biological Psychiatry 1992 32 756-765. (doi:10.1016/0006- 3223(92)90079-F)
47. Simmons NE, Do HM, Lipper MH & Laws ER Jr. Cerebral atrophy in Cushing's disease. Surgical Neurology 2000 53 72-76. (doi:10.1016/S0090-3019(99) 00197-4)
48. Wagenmakers MA, Netea-Maier RT, Prins JB, Dekkers T, den Heijer M & Hermus AR. Impaired quality of life in patients in long-term remission of Cushing's syndrome of both adrenal and pituitary origin: a remaining effect of long-standing hypercortisolism? European Journal of Endocrinology 2012 167 687-695. (doi:10.1530/EJE-12-0308)
49. Ragnarsson O, Berglund P, Eder DN & Johannsson G. Long-term cognitive impairments and attentional deficits in patients with Cushing's disease and cortisol-producing adrenal adenoma in remission. Journal of Clinical Endocrinology and Metabolism 2012 97 E1640-E1648. (doi:10.1210/jc.2012-1945)
50. van Aken MO, Pereira AM, Biermasz NR, van Thiel SW, Hoftijzer HC, Smit JW, Roelfsema F, Lamberts SW & Romijn JA. Quality of life in patients after long-term biochemical cure of Cushing's disease. Journal of Clinical Endocrinology and Metabolism 2005 90 3279-3286. (doi:10.1210/jc.2004-1375)
51. Hawn MT, Cook D, Deveney C & Sheppard BC. Quality of life after laparoscopic bilateral adrenalectomy for Cushing's disease. Surgery 2002 132 1064-1068 (discussion 1068-1069). (doi:10.1067/msy.2002.128482)
52. Jeffcoate WJ, Silverstone JT, Edwards CR & Besser GM. Psychiatric manifestations of Cushing's syndrome: response to lowering of plasma cortisol. Quarterly Journal of Medicine 1979 48 465-472.
53. Dorn LD, Burgess ES, Friedman TC, Dubbert B, Gold PW & Chrousos GP. The longitudinal course of psychopathology in Cushing's syndrome after correction of hypercortisolism. Journal of Clinical Endocrinology and Metabolism 1997 82 912-919. (doi:10.1210/jc.82.3.912)
54. Tiemensma J, Biermasz NR, Middelkoop HA, van der Mast RC, Romijn JA & Pereira AM. Increased prevalence of psychopathology and maladaptive personality traits after longterm cure of Cushing's disease. Journal of Clinical Endocrinology and Metabolism 2010 95 E129-E141. (doi:10.1210/jc.2010-0512)
55. Starkman MN, Giordani B, Gebarski SS & Schteingart DE. Improvement in learning associated with increase in hippocampal formation volume. Biological Psychiatry 2003 53 233-238. (doi:10.1016/S0006-3223(02)01750-X)
56. Dorn LD & Cerrone P. Cognitive function in patients with Cushing syndrome: a longitudinal perspective. Clinical Nursing Research 2000 9 420-440. (doi:10.1177/10547730022158672)
57. Forget H, Lacroix A & Cohen H. Persistent cognitive impairment following surgical treatment of Cushing's syndrome. Psychoneuroendocrinology 2002 27 367-383. (doi:10.1016/S0306-4530(01)00059-2)
58. Bourdeau I, Bard C, Noel B, Leclerc I, Cordeau MP, Belair M, Lesage J, Lafontaine L & Lacroix A. Loss of brain volume in endogenous Cushing's syndrome and its reversibility after correction of hypercortisolism. Journal of Clinical Endocrinology and Metabolism 2002 87 1949-1954. (doi:10.1210/jc.87.5. 1949)
59. Starkman MN, Giordani B, Gebarski SS, Berent S, Schork MA & Schteingart DE. Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing's disease. Biological Psychiatry 1999 46 1595-1602. (doi:10.1016/S0006-3223(99)00203-6)
60. Tiemensma J, Kokshoorn NE, Biermasz NR, Keijser BJ, Wassenaar MJ, Middelkoop HA, Pereira AM & Romijn JA. Subtle cognitive impairments in patients with long-term cure of Cushing's disease. Journal of Clinical Endocrinology and Metabolism 2010 95 2699-2714. (doi:10.1210/jc.2009-2032)
61. Resmini E, Santos A, Gomez-Anson B, Vives Y, Pires P, Crespo I, Portella MJ, de Juan-Delago M, Barahona MJ & Webb SM. Verbal and visual memory performance and hippocampal volumes, measured by 3-tesla magnetic resonance imaging, in patients with Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 2012 97 663-671. (doi:10.1210/jc.2011-2231)
62. Merke DP, Giedd JN, Keil MF, Mehlinger SL, Wiggs EA, Holzer S, Rawson E, Vaituzis AC, Stratakis CA & Chrousos GP. Children experience cognitive decline despite reversal of brain atrophy one year after resolution of Cushing syndrome. Journal of Clinical Endocrinology and Metabolism 2005 90 2531-2536. (doi:10.1210/jc.2004-2488)
63. Keil MF, Merke DP, Gandhi R, Wiggs EA, Obunse K & Stratakis CA. Quality of life in children and adolescents 1-year after cure of Cushing syndrome: a prospective study. Clinical Endocrinology 2009 71 326-333. (doi:10.1111/j.1365-2265.2008.03515.x)
64. Herbert J, Goodyer IM, Grossman AB, Hastings MH, de Kloet ER, Lightman SL, Lupien SJ, Roozendaal B & Seckl JR. Do corticosteroids damage the brain? Journal of Neuroendocrinology 2006 18 393-411. (doi:10.1111/j.1365-2826.2006. 01429.x)
65. Groeneweg FL, Karst H, de Kloet ER & Joels M. Rapid nongenomic effects of corticosteroids and their role in the central stress response. Journal of Endocrinology 2011 209 153-167. (doi:10.1530/JOE-10-0472)
66. Tata DA & Anderson BJ. The effects of chronic glucocorticoid exposure on dendritic length, synapse numbers and glial volume in animal models: implications for hippocampal volume reductions in depression. Physiology & Behavior 2010 99 186-193. (doi:10.1016/j.physbeh.2009.09.008)
67. Resmini E, Santos A, Gomez-Anson B, Lopez-Mourelo O, Pires P, Vives-Gilabert Y, Crespo I, Portella MJ, de Juan-Delago M & Webb SM. Hippocampal dysfunction in cured Cushing's syndrome patients, detected by H-MR-spectroscopy. Clinical Endocrinology 2013. In press. (doi:10.1111/cen. 12224)
68. Johansson P, Johansson JO, Labrie F, Mattsson N, Hansson O, Blennow K, Zetterberg H,Wallin A, Ohlsson C & Svensson J. Mild dementia is associated with increased adrenal secretion of cortisol and precursor sex steroids in women. Clinical Endocrinology 2011 75 301-308. (doi:10.1111/j.1365-2265.2011. 04082.x)
69. Huang CW, Lui CC, Chang WN, Lu CH, Wang YL & Chang CC. Elevated basal cortisol level predicts lower hippocampal volume and cognitive decline in Alzheimer's disease. Journal of Clinical Neuroscience 2009 16 1283-1286. (doi:10.1016/j.jocn.2008.12.026)
70. Johansson P, Mattsson N, Hansson O, Wallin A, Johansson JO, Andreasson U, Zetterberg H, Blennow K & Svensson J. Cerebrospinal fluid biomarkers for Alzheimer's disease: diagnostic performance in a homogeneous mono-center population. Journal of Alzheimer's Disease 2011 24 537-546. (doi:10.3233/JAD- 2011-101878)
71. Zetterberg H, Mattsson N & Blennow K. Cerebrospinal fluid analysis should be considered in patients with cognitive problems. International Journal of Alzheimer's Disease 2010 2010 163065. (doi:10.4061/2010/163065)
72. Ragnarsson O, Berglund P, Eder DN, Zetterberg H, Hietala MA, Blennow K & Johannsson G. Neurodegenerative and inflammatory biomarkers in cerebrospinal fluid in patients with Cushing's syndrome in remission. European Journal of Endocrinology 2013 169 211-215. (doi:10.1530/EJE-13-0205)
73. Lambert JK, Goldberg L, Fayngold S, Kostadinov J, Post KD & Geer EB. Predictors of mortality and long-term outcomes in treated Cushing's disease: a study of 346 patients. Journal of Clinical Endocrinology and Metabolism 2013 98 1022-1030. (doi:10.1210/jc.2012-2893)
74. Rollin GA, Ferreira NP, Junges M, Gross JL & Czepielewski MA. Dynamics of serum cortisol levels after transsphenoidal surgery in a cohort of patients with Cushing's disease. Journal of Clinical Endocrinology and Metabolism 2004 89 1131-1139. (doi:10.1210/jc.2003-031170)
75. Lindsay JR, Oldfield EH, Stratakis CA & Nieman LK. The postoperative basal cortisol and CRH tests for prediction of long-term remission from Cushing's disease after transsphenoidal surgery. Journal of Clinical Endocrinology and Metabolism 2011 96 2057-2064. (doi:10.1210/jc.2011-0456)
76. Esposito F, Dusick JR, Cohan P, Moftakhar P, McArthur D, Wang C, Swerdloff RS & Kelly DF. Clinical review: Early morning cortisol levels as a predictor of remission after transsphenoidal surgery for Cushing's disease. Journal of Clinical Endocrinology and Metabolism 2006 91 7-13. (doi:10.1210/jc.2005-1204)
77. Klose M, Jorgensen K & Kristensen LO. Characteristics of recovery of adrenocortical function after treatment for Cushing's syndrome due to pituitary or adrenal adenomas. Clinical Endocrinology 2004 61 394-399. (doi:10.1111/j.1365-2265.2004.02111.x)
78. Estrada J, Garcia-Uria J, Lamas C, Alfaro J, Lucas T, Diez S, Salto L & Barcelo B. The complete normalization of the adrenocortical function as the criterion of cure after transsphenoidal surgery for Cushing's disease. Journal of Clinical Endocrinology and Metabolism 2001 86 5695-5699. (doi:10.1210/jc.86.12.5695)
79. Lodish M, Dunn SV, Sinaii N, Keil MF & Stratakis CA. Recovery of the hypothalamic-pituitary-adrenal axis in children and adolescents after surgical cure of Cushing's disease. Journal of Clinical Endocrinology and Metabolism 2012 97 1483-1491. (doi:10.1210/jc.2011-2325)
80. Bhattacharyya A, Kaushal K, Tymms DJ & Davis JR. Steroid withdrawal syndrome after successful treatment of Cushing's syndrome: a reminder. European Journal of Endocrinology 2005 153 207-210. (doi:10.1530/eje.1.01953)
81. Dahlqvist P, Bensing S, Ekwall O,Wahlberg J, Bergthorsdottir R & Hulting AL. A national medical emergency card for adrenal insufficiency. A new warning card for better management and patient safety. Lakartidningen 2011 108 2226-2227.
82. Odagiri E, Yamanaka Y, Ishiwatari N, Jibiki K, Demura R, Demura H, Suda T & Shizume K. Studies on pituitary-gonadal function in patients with Cushing's syndrome. Endocrinologia Japonica 1988 35 421-427. (doi:10.1507/endocrj1954.35.421)
83. Mathioudakis N, Thapa S, Wand GS & Salvatori R. ACTHsecreting pituitary microadenomas are associated with a higher prevalence of central hypothyroidism compared to other microadenoma types. Clinical Endocrinology 2012 77 871-876. (doi:10.1111/j.1365-2265.2012.04442.x)
84. Marazuela M, Cuerda C, Lucas T, Vicente A, Blanco C & Estrada J. Anterior pituitary function after adrenalectomy in patients with Cushing's syndrome. Postgraduate Medical Journal 1993 69 547-551. (doi:10.1136/pgmj.69. 813.547)
85. Luton JP, Thieblot P, Valcke JC, Mahoudeau JA & Bricaire H. Reversible gonadotropin deficiency in male Cushing's disease. Journal of Clinical Endocrinology and Metabolism 1977 45 488-495. (doi:10.1210/jcem-45-3- 488)
86. Stratakis CA, Mastorakos G, Magiakou MA, Papavasiliou E, Oldfield EH & Chrousos GP. Thyroid function in children with Cushing's disease before and after transsphenoidal surgery. Journal of Pediatrics 1997 131 905-909. (doi:10.1016/S0022-3476(97)70041-6)
87. Doherty GM, Nieman LK, Cutler GB Jr, Chrousos GP & Norton JA. Time to recovery of the hypothalamic-pituitary-adrenal axis after curative resection of adrenal tumors in patients with Cushing's syndrome. Surgery 1990 108 1085-1090.
88. Tan HS, Thai AC, Nga ME & Mukherjee JJ. Development of ipsilateral adrenocortical carcinoma sixteen years after resection of an adrenal tumour causing Cushing's syndrome. Annals of the Academy of Medicine, Singapore 2005 34 271-274.
89. Meyer A & Behrend M. Cushing's syndrome: adrenalectomy and long-term results. Digestive Surgery 2004 21 363-370. (doi:10.1159/000081353)
90. Sherlock M, Ayuk J, Tomlinson JW, Toogood AA, Aragon- Alonso A, Sheppard MC, Bates AS & Stewart PM. Mortality in patients with pituitary disease. Endocrine Reviews 2010 31 301-342. (doi:10.1210/er.2009-0033)
91. Rosen T & Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990 336 285-288. (doi:10.1016/0140-6736(90) 91812-O)
92. Svensson J, Bengtsson BA, Rosen T, Oden A & Johannsson G. Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. Journal of Clinical Endocrinology and Metabolism 2004 89 3306-3312. (doi:10.1210/jc.2003-031601)
93. Brada M, Ashley S, Ford D, Traish D, Burchell L & Rajan B. Cerebrovascular mortality in patients with pituitary adenoma. Clinical Endocrinology 2002 57 713-717. (doi:10.1046/j.1365-2265.2002.01570.x)
94. Gaillard RC, Mattsson AF, Akerblad AC, Bengtsson BA, Cara J, Feldt-Rasmussen U, Koltowska-Haggstrom M, Monson JP, Saller B, Wilton P et al. Overall and cause-specific mortality in GH-deficient adults on GH replacement. European Journal of Endocrinology 2012 166 1069-1077. (doi:10.1530/EJE-11-1028)
95. Tzanela M, Karavitaki N, Stylianidou C, Tsagarakis S & Thalassinos NC. Assessment of GH reserve before and after successful treatment of adult patients with Cushing's syndrome. Clinical Endocrinology 2004 60 309-314. (doi:10.1046/j.1365-2265.2004.01976.x)
96. Hoybye C, Ragnarsson O, Jonsson PJ, Koltowska-Haggstrom M, Trainer P, Feldt-Rasmussen U & Biller BM. Clinical features of GH deficiency and effects of 3 years of GH replacement in adults with controlled Cushing's disease. European Journal of Endocrinology 2010 162 677-684. (doi:10.1530/EJE-09-0836)
97. Falleti MG, Maruff P, Burman P & Harris A. The effects of growth hormone (GH) deficiency and GH replacement on cognitive performance in adults: a meta-analysis of the current literature. Psychoneuroendocrinology 2006 31 681-691. (doi:10.1016/j.psyneuen.2006.01.005)
98. Oertel H, Schneider HJ, Stalla GK, Holsboer F & Zihl J. The effect of growth hormone substitution on cognitive performance in adult patients with hypopituitarism. Psychoneuroendocrinology 2004 29 839-850. (doi:10.1016/S0306- 4530(03)00151-3)
99. Bensing S, Brandt L, Tabaroj F, Sjoberg O, Nilsson B, Ekbom A, Blomqvist P & Kampe O. Increased death risk and altered cancer incidence pattern in patients with isolated or combined autoimmune primary adrenocortical insufficiency. Clinical Endocrinology 2008 69 697-704. (doi:10.1111/j.1365-2265. 2008.03340.x)
100. BergthorsdottirR, Leonsson-ZachrissonM,OdenA&JohannssonG. Premature mortality in patients with Addison's disease: a population-based study. Journal of Clinical Endocrinology and Metabolism 2006 91 4849-4853. (doi:10.1210/jc. 2006-0076)
101. Sherlock M, Reulen RC, Alonso AA, Ayuk J, Clayton RN, Sheppard MC, Hawkins MM, Bates AS & Stewart PM. ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 2009 94 4216-4223. (doi:10.1210/jc.2009-1097)
102. Esteban NV, Loughlin T, Yergey AL, Zawadzki JK, Booth JD, Winterer JC & Loriaux DL. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. Journal of Clinical Endocrinology and Metabolism 1991 72 39-45. (doi:10.1210/jcem-72-1-39)
103. Filipsson H, Monson JP, Koltowska-Haggstrom M, Mattsson A & Johannsson G. The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. Journal of Clinical Endocrinology and Metabolism 2006 91 3954-3961. (doi:10.1210/jc.2006-0524)
104. Ragnarsson O, Nystrom HF & Johannsson G. Glucocorticoid replacement therapy is independently associated with reduced bone mineral density in women with hypopituitarism. Clinical Endocrinology 2012 76 246-252. (doi:10.1111/j.1365-2265.2011.04174.x)
105. Zelissen PM, Croughs RJ, van Rijk PP & Raymakers JA. Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease. Annals of Internal Medicine 1994 120 207-210. (doi:10.7326/0003-4819-120-3-199402010-00005)
106. Bleicken B, Hahner S, Loeffler M, Ventz M, Decker O, Allolio B & Quinkler M. Influence of hydrocortisone dosage scheme on health-related quality of life in patients with adrenal insufficiency. Clinical Endocrinology 2010 72 297-304. (doi:10.1111/j.1365-2265.2009.03596.x)
107. Hahner S, Loeffler M, Fassnacht M, Weismann D, Koschker AC, Quinkler M, Decker O, Arlt W & Allolio B. Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. Journal of Clinical Endocrinology and Metabolism 2007 92 3912-3922. (doi:10.1210/jc.2007-0685)
108. Johannsson G, Nilsson AG, Bergthorsdottir R, Burman P, Dahlqvist P, Ekman B, Engstrom BE, Olsson T, Ragnarsson O, Ryberg M et al. Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. Journal of Clinical Endocrinology and Metabolism 2012 97 473-481. (doi:10.1210/jc.2011-1926)
109. Burman P, Mattsson AF, Johannsson G, Hoybye C, Holmer H, Dahlqvist P, Berinder K, Engstrom BE, Ekman B, Erfurth EM et al. Deaths among adult patients with hypopituitarism: hypocortisolism during acute stress, and de novo malignant brain tumors contribute to an increased mortality. Journal of Clinical Endocrinology and Metabolism 2013 98 1466-1475. (doi:10.1210/jc.2012-4059)
110. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007 30 162-172. (doi:10.2337/dc07-9917)
111. Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a joint consensus conference of the Growth Hormone Research Society and the Pituitary Society. Journal of Clinical Endocrinology and Metabolism 2004 89 3099-3102. (doi:10.1210/jc.2003-031138)
112. Peacey SR, Guo CY, Robinson AM, Price A, Giles MA, Eastell R & Weetman AP. Glucocorticoid replacement therapy: are patients over treated and does it matter? Clinical Endocrinology 1997 46 255-261. (doi:10.1046/j.1365- 2265.1997.780907.x)
113. Wuster C, Abs R, Bengtsson BA, Bennmarker H, Feldt-Rasmussen U, Hernberg-Stahl E, Monson JP, Westberg B & Wilton P. The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. Journal of Bone and Mineral Research 2001 16 398-405. (doi:10.1359/jbmr.2001.16.2.398)
114. Holmes SJ, Economou G,Whitehouse RW, Adams JE & Shalet SM. Reduced bone mineral density in patients with adult onset growth hormone deficiency. Journal of Clinical Endocrinology and Metabolism 1994 78 669-674. (doi:10.1210/jc.78.3.669)
115. Doga M, Bonadonna S, Gola M, Mazziotti G, Nuzzo M & Giustina A. GH deficiency in the adult and bone. Journal of Endocrinological Investigation 2005 28 18-23.
116. Tritos NA, Greenspan SL, King D, Hamrahian A, Cook DM, Jonsson PJ, Wajnrajch MP, Koltowska-Haggstrom M & Biller BM. Unreplaced sex steroid deficiency, corticotropin deficiency, and lower IGF-I are associated with lower bone mineral density in adults with growth hormone deficiency: a KIMS database analysis. Journal of Clinical Endocrinology and Metabolism 2011 96 1516-1523. (doi:10.1210/jc.2010-2662)
117. Tiemensma J, Kaptein AA, Pereira AM, Smit JW, Romijn JA & Biermasz NR. Coping strategies in patients after treatment for functioning or nonfunctioning pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 2011 96 964-971. (doi:10.1210/jc.2010-2490)
118. Mauri M, Sinforiani E, Bono G, Vignati F, Berselli ME, Attanasio R & Nappi G. Memory impairment in Cushing's disease. Acta Neurol Scand 1993 87 52-55.
119. Hook JN, Giordani B, Schteingart DE, Guire K, Giles J, Ryan K, Gebarski SS, Langenecker SA & Starkman MN. Patterns of cognitive change over time and relationship to age following successful treatment of Cushing's disease. J Int Neuropsychol Soc 2007 13 21-29.